The Supervisory Board of Biotest AG appointed Peter Janssen as a further member of the company's Management Board with effect from September 1st, 2022. As a Management Board Member, Mr. Janssen will initially familiarise himself with the area of responsibility of Dr. Georg Floß and will formally succeed him as Chief Operating Officer at the end of the year after Georg Floß leaves the company as planned when his contract expires. Mr. Janssen served as Executive Vice President for Prothya Biosolutions, following a successful business transformation as CEO of the company in Belgium since 2017.

Prior to joining Prothya, Mr. Janssen spent 14 years with Pfizer and five years with its animal health spin-off Zoetis, where he held various transformative, strategic and operational roles of increasing responsibility. As part of his academic training, he holds a Master of Science in Electromechanical Engineering, a Master in Applied Economics and several business degrees.